ARTA
HBIO icon

A.R.T. Advisors’s Harvard Bioscience HBIO Stock Holding History

A.R.T. Advisors’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,119
Closed -$36K – 1424
2018
Q4 		$36K Buy
1,119
+76
+7% +$3K ﹤0.01% 1231
2018
Q3 		$54K Buy
+1,043
New +$58.5K ﹤0.01% 1314

Other funds holding HBIO

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

A.R.T. Advisors's HBIO Position: Q1 2019 in Review

A.R.T. Advisors sold out of Harvard Bioscience (HBIO) in Q1 2019, closing a stake of 1,119 shares — an estimated $36K sold.

A.R.T. Advisors first reported a position in HBIO in Q3 2018 and held it in 2 quarters. The position peaked at $54K in Q3 2018. 87 funds tracked by Wall St. Rank hold HBIO as of Q1 2019.

  • A.R.T. Advisors reported no remaining Harvard Bioscience position as of Q1 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 1,119 Harvard Bioscience shares in Q1 2019, an estimated $36K.
  • A.R.T. Advisors first reported a position in Harvard Bioscience in Q3 2018 and held it in 2 quarters.
  • A.R.T. Advisors's Harvard Bioscience position peaked at $54K in Q3 2018.
  • 87 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2019.

Based on A.R.T. Advisors's 13F filing for Q1 2019, filed 15 May 2019.